Cardiology

Mount Sinai study is the first to identify that heart attack, stroke and heart failure are linked to a specific type of age-related macular degeneration.

According to a study, use is linked to a lower prevalence of age-related macular degeneration in European populations.

US Preventive Services Task Force hasn't endorsed screening for atrial fibrillation. Findings from these two studies might factor into a reconsideration.

Mavacamten improves functional capacity and symptoms in adults with New York Heart Association class II-III obstructive HCM.

New research looks at the potential benefits of long-term statin use in patients who are at increased risk of cardiovascular disease.

Used to treat a variety of concerns and found in many medicine cabinets, new research indicates that nonsteroidal anti-inflammatory drugs may pose a risk to patients with type 2 diabetes.

Lack of blood clotting may afford some protection against common cardiovascular disease events, such as ischemic stroke.

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

An analysis of nationally representative data from NHANES cycles from 1999-2000 through 2017-2018 suggests just 6.8% of US adults had optimal cardiometabolic health.

Hypertension adversely impacts the multiple sclerosis (MS) disease course and is more common among Black Americans.

The American College of Cardiology and patient groups pushed the PBM to reverse its decision to take Eliquis off its formularies. CVS Caremark says it changed course after negotiating a lower net price.

An analysis of data from a Cleveland Clinic database indicates calcium supplementation in older adults with aortic stenosis was linked to an increased risk of mortality and worsening aortic stenosis.

Class 1C antiarrhythmic drugs were associated with the lowest rate of adverse outcomes.

The approval indicates the SGLT2 inhibitor for reducing risk of CV death and hospitalizations for heart failure in adults with heart failure.

American Heart Month is a great time for pharmacists to educate the public about their contributions to managing patients with cardiovascular disease.

The EMPEROR-Preserved study investigated empagliflozin (Jardiance; Eli Lilly) for the treatment of heart failure with preserved ejection fraction.

An oral abstract presentation at the American Diabetes Association Virtual 81st Scientific Sessions highlighted a cardioprotective benefit of sodium-glucose co-transporter-2 inhibitors.

A poster presented at the American Diabetes Association Virtual 81st Scientific Sessions highlighted the effect of a physician-pharmacist collaborative management team in diabetes preventative care services.

The FDA approved Pradaxa (dabigatran etexilate) to treat venous thromboembolism in children aged 3 months to less than 12 years.

Blood-brain barrier crossing medicines have shown memory benefits in elderly patients, according to a new analysis.

Community model for hypertension management drives increased access, better outcomes for patients.

Individuals with prediabetes may be at increased risk of suffering an adverse cardiovascular event.

A new drug review for vericiguat, indicated for heart failure, reports efficacy and safety data.

The study incorporated diverse populations to determine the association between diets with a high glycemic index and cardiovascular disease risk.

Hispanic and Latino adults have a high prevalence of cardiovascular risk factors, but many are receiving inadequate treatment.

The American Heart Association published a special issue to discuss current research in cardiovascular disease and outcomes in women.

Investigators used MRI scans of the heart to identify whether heart injury was caused by COVID-19 infection.

New clinical practice guidelines call for lowering blood pressure levels down to 120 mmHg systolic for those with chronic kidney disease.

Once-weekly semaglutide 2.4 mg resulted in sustained reductions in weight for those who are overweight or obese, the investigators reported.

Novartis’ sacubitril/valsartan (Entresto) is now indicated for use in the treatment of chronic heart failure.